The successful combination of ovarian function suppression with endocrine therapies (55) and the recent inclusion of premenopausal metastatic HR+ breast cancer patients in phase III clinical trials testing CDK4/6 inhibitors clearly demonstrated benefit for young HR+ patients (56), presenting an expanded choice of treatment options. This evidence concerns the gene CDK4 and breast carcinoma.